CLNN · Clene Inc.

Clene Inc. has entered into a material definitive agreement to raise capital through an underwritten public offering. The company agreed to sell 1,000,000 shares of its common stock at a price of $7.00 per share, targeting gross proceeds of approximately $7 million. After accounting for underwriting discounts of 6.5% and estimated expenses of $140,000, the company expects to receive net proceeds of approximately $6.4 million. The financing is led by Canaccord Genuity LLC as the sole bookrunner, with Maxim Group LLC and D. Boral Capital LLC serving as financial advisors. The transaction includes a 60-day lock-up agreement restricting the sale of securities by the company and certain insiders. Proceeds are intended to advance the company's lead drug candidate, CNM-Au8, specifically funding the preparation and filing of a New Drug Application (NDA), supporting ongoing and future clinical trials, and expanding manufacturing capabilities. The offering is conducted under the company's effective shelf registration statement on Form S-3.